Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement

American Journal of Clinical Nutrition

Volumn 69, Issue 2, 1999, Pages 231-236

  Heber, David ^a,b   Yip, Ian ^c   Ashley, Judith M ^c   Elashoff, David A ^c   Elashoff, Robert M ^c   Go, Vay Liang W ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Pharmanex Inc   (United States)

^c NONE

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Chinese red yeast rice; Dietary supplement; High density lipoprotein cholesterol; HMG CoA; Lipid lowering rice food; Low density lipoprotein cholesterol; Monascus purpureus; Placebo treatment; Triacylglycerol

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG FORMULATION; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RICE; YEAST;

EID: 0032898925     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/69.2.231     Document Type: Article

References (24)

1. Stuart MD. Chinese materia medica - vegetable kingdom. Taipai, Republic of China: Southern Materials Center, Inc, 1979.
2. Ying Sing S, T'ien Jung K'ai Wu - Chinese technology in the seventeenth century. Sun E-T and Sun S-C, transl. London: Pennsylvania State University Press, 1966;291-4.
3. Zhu Y, Li CL, Wang YY. Effects of Xuezhikang on blood lipids and lipoprotein concentrations of rabbits and quails with hyperlipidemia. Chin J Pharmacol 1995;30:4-8.
4. Li CL, Li YF, Hou ZL. Xuezhikang toxicity study. Bull Chinese Pharmacol Soc 1995:12:3.
5. Zhu Y, Li CL, Wang YY, Zhu JS, Chang J, Kritchevsky D. Monascus purpureus (red yeast): a natural product that lowers blood cholesterol in animal models of hypercholesterolemia. Nutr Res 1998;18:71-81.
6. Wang J, Su M, Lu Z, et al. Clinical trial of extract of Monascus purpureus (red yeast) in the treatment of hyperlipidemia. Chin J Exp Ther Prep Chin Med 1995;12:1-5.
7. Shen Z, Yu P, Su M, et al. A prospective study on Zhitai capsule in the treatment of primary hyperlipidemia. Nat Med J China 1996;76:156-7.
8. Mei F. Red yeast flavored duck. In: Fang Mei's illustrated cookbook of regional Chinese cuisine. Guangxi, China: Guangxi National Press, 1990;177-88.
9. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
10. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
11. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
12. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results. JAMA 1984;251:351-74.
13. Kristal AR, Shattuck AL, Henry HJ. Patterns of dietary behavior associated with selecting diets low in fat: Reliability and validity of a behavioral approach to dietary assessment. J Am Diet Assoc 1990; 90:214-20.
14. Lipid Research Clinics Program. Manual of laboratory operations. Volume I. Lipid and lipoprotein analysis. Bethesda, MD: National Heart Lung Institute. National Institutes of Health, 1974;1:499-502.
15. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res 1978;19:65-73.
16. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
17. Fisher LD, Van Belle G. Biostatistics: a methodology for the health sciences. New York: John Wiley & Sons, Inc, 1993.
18. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull 1945;1:80-3.
19. Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, 1975.
20. Endo A. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo) 1979;32:852-4.
21. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-efficacy and safety follow-up. Am J Cardiol 1994;74:667-73.
22. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with Lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-22.
23. Pearson TA. Commentary: lipid-lowering therapy in low-risk patients. JAMA 1998;279:1659-61.
24. Perreault S, Hamilton VH, Lavoie F, Grover S. Treating hyperlipidemia for the primary prevention of coronary disease: are higher doses of lovostatin cost-effective? Arch Intern Med 1998;158:375-81.